A5062920021- Metabolism, Diabetes, and Cancer
- Diabetes Treatment and Management
- Cancer Immunotherapy and Biomarkers
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Venous Thromboembolism Diagnosis and Management
- Neuroendocrine Tumor Research Advances
- Mast cells and histamine
- Ferroptosis and cancer prognosis
- COVID-19 Clinical Research Studies
- Pneumonia and Respiratory Infections
- Lung Cancer Treatments and Mutations
- Asthma and respiratory diseases
- Health disparities and outcomes
- Heparin-Induced Thrombocytopenia and Thrombosis
- Potassium and Related Disorders
- Chemotherapy-induced cardiotoxicity and mitigation
- Pharmacology and Obesity Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Sarcoidosis and Beryllium Toxicity Research
- Respiratory Support and Mechanisms
- Cancer Treatment and Pharmacology
- Neuroscience of respiration and sleep
- Cancer, Lipids, and Metabolism
Unity Hospital
2022-2025
Unity Health System
2022-2025
Chung Shan Medical University
2022
Chung Shan Medical University Hospital
2022
Objectives Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF mortality among with cancer diabetes. Methods This was a retrospective propensity score-matched cohort study involving adult type 2 diabetes mellitus diagnosed between January 2010 December 2021. The primary outcomes were hospitalisation for incident all-cause mortality. secondary serious adverse events...
Abstract Introduction Obstructive sleep apnea (OSA) is associated with an elevated thromboembolic risk due to comorbidities, reduced mobility, chronic inflammation, and a hypercoagulable state. Glucagon-like peptide-1 (GLP-1) analogs, including glucagon-like receptor agonists (GLP-1 RAs) glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 co-agonists, have shown potential in reducing thrombotic effects. However, the impact of GLP-1 analogs on OSA patients remains unclear. Methods We...
Patients with COPD on triple therapy often face exacerbations and comorbidities. Emerging evidence suggests that glucagon-like peptide-1 (GLP-1) analogues may reduce the risk of exacerbation in patients type 2 diabetes mellitus (T2DM). This study investigates impact GLP-1 pulmonary outcomes single-inhaler (SITT) T2DM. We conducted a retrospective cohort using TriNetX database analysed adult T2DM who received SITT between April 2005 July 2023. were categorised into analogue dipeptidyl...
Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs), but the impact of lipophilic and hydrophilic statin properties on patient is unknown.We aim to investigate if statins clinical ICIs.We conducted a retrospective cohort study at two tertiary referral centers Taiwan comprising ICIs between January 2015 December 2021. We compared comparative effect outcomes. The primary outcome was overall (OS) secondary progression-free (PFS).Among...
Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator-activated receptor-γ (PPAR-γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte-mediated antitumor activity.We conducted a retrospective cohort study to investigate the impact of PPAR-γ-activating ARBs on patient survival in patients treated immune checkpoint inhibitors (ICIs) across all types cancers.A total 167 receiving both were included....
e21078 Background: H1-antihistamines are long-used medications for the treatment of allergies. In preclinical studies, antihistamines, particularly those with cationic amphiphilic properties, have been found to anti-tumor effects. observational associated improved survival in patients receiving immune checkpoint inhibitors (ICIs) pan-cancer association studies. However, impact antihistamines on lung cancer is unclear. We aim evaluate effect ICIs. Methods: conducted a retrospective cohort...